A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis

NCT00282347 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Nephritis

Interventions

DRUG: Rituximab
DRUG: Placebo
DRUG: Mycophenolate mofetil
DRUG: Methylprednisolone
DRUG: Diphenhydramine
DRUG: Acetaminophen
DRUG: Prednisone

Sponsor

Genentech, Inc.